Poolbeg Pharma (AIM: POLB; OTC: POLBF; FRA: POLBF) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the company clinical trial authorization for its TOPICAL trial with...
Prelude Therapeutics (NASDAQ: PRLD) has appointed Dr. Charles Morris as chief medical officer (CMO), effective April 20, 2026. Dr. Morris is a medical oncologist with more than 30 years of oncology drug development...
The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk...
Actuate Therapeutics (NASDAQ: ACTU) has announced the publication of new data in Nature Medicine from its Phase 2 clinical trial evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP)...
Cellectar Biosciences (NASDAQ: CLRB) has announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 (CLR 125) for the potential treatment of triple negative breast cancer (TNBC). According to...
MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim...
Firefly Neuroscience (NASDAQ: AIFF) has achieved a major operational and commercial milestone with more than 200,000 EEG/ERP (human brain function) scans. Through its acquisition of Evoke Neuroscience in May 2025...
OS Therapies (NYSE American: OSTX) has appointed Robert S. Langer, PhD, and co-founder of Moderna, to its strategic advisory board. According to OS, Dr. Langer will assist management with prioritizing the listeria...
MetaVia (NASDAQ: MTVA) has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. According to MetaVia, Part 3...
Annovis Bio (NYSE: ANVS) has announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds extending its cash runway through Phase 3 Alzheimer’s disease (AD) six-month NDA...